Sunshine Biopharma, Inc. (SBFM)
NASDAQ: SBFM · Real-Time Price · USD
2.180
+0.040 (1.87%)
At close: Jun 26, 2026, 4:00 PM EDT
2.080
-0.100 (-4.59%)
After-hours: Jun 26, 2026, 7:49 PM EDT

Company Description

Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada.

The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer.

It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products.

In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications.

Sunshine The company is based in Fort Lauderdale, Florida.

Sunshine Biopharma, Inc.
Sunshine Biopharma logo
Country United States
Founded 2006
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 50
CEO Steve Slilaty

Contact Details

Address:
333 Las Olas Way, CU4 Suite 433
Fort Lauderdale, Florida 33301
United States
Phone 954 330 0684
Website sunshinebiopharma.com

Stock Details

Ticker Symbol SBFM
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001402328
CUSIP Number 867781809
ISIN Number US8677818093
Employer ID 20-5566275
SIC Code 2834

Key Executives

Name Position
Dr. Steve N. Slilaty Ph.D. Chairman, President and Chief Executive Officer
Camille Sebaaly Chief Financial Officer, Secretary and Director
Michel Roy Chief Commercial Officer
Malek Chamoun Chief Development Officer
Robert G. Ferreira President of Sunshine Bio Investments Inc

Latest SEC Filings

Date Type Title
Jun 8, 2026 DEF 14C Filing
May 29, 2026 PRE 14C Filing
May 29, 2026 8-K Current Report
May 22, 2026 SCHEDULE 13G Filing
May 21, 2026 SCHEDULE 13G Filing
May 19, 2026 8-K Current Report
May 19, 2026 424B4 Prospectus
May 18, 2026 EFFECT Notice of Effectiveness
May 13, 2026 10-Q Quarterly Report
May 12, 2026 S-1 General form for registration of securities under the Securities Act of 1933